Targeting the TGFβ signalling pathway in disease

Nature Reviews Drug Discovery

Volumn 11, Issue 10, 2012, Pages 790-811

  Akhurst, Rosemary J ^a   Hata, Akiko ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BELAGENPUMATUCEL L; CANDESARTAN; DABRAFENIB; DECORIN; DISITERTIDE; FIBROMODULIN; FRESOLIMUMAB; IMC TR 1; LERDELIMUMAB; LEUCYLSERYLLYSYLLEUCINE; LOMUSTINE; LOSARTAN; LY 2109761; LY 2157299; LY 2382770; METELIMUMAB; MONOCLONAL ANTIBODY; P 17; PEPTIDE; PEPTIDOMIMETIC AGENT; PIRFENIDONE; SORAFENIB; STX 100; TRABEDERSEN; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB;

BREAST CANCER; BREAST METASTASIS; CANCER RADIOTHERAPY; CELL PROLIFERATION; COLON CANCER; COMBINATION CHEMOTHERAPY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG RESISTANCE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; FOCAL GLOMERULOSCLEROSIS; GLIOBLASTOMA; HUMAN; IMMUNE DEFICIENCY; IN-STENT RESTENOSIS; INFLAMMATION; KERATOACANTHOMA; KIDNEY CARCINOMA; KIDNEY FIBROSIS; LIVER INJURY; LUNG NON SMALL CELL CANCER; MARFAN SYNDROME; METASTATIC MELANOMA; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; MYOFIBROBLAST; NONHUMAN; OCULAR FIBROSIS; PANCREAS CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PTERYGIUM; REVIEW; SCAR FORMATION; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN DEFECT; SKIN FIBROSIS; SQUAMOUS CELL CARCINOMA; SYSTEMIC SCLEROSIS;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; PROTEIN BINDING; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84866985855     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3810     Document Type: Review

References (232)

1. Schmierer, B. & Hill, C. S. TGFβ-SMAD signal transduction: molecular specificity and functional flexibility. Nature Rev. Mol. Cell Biol. 8, 970-982 (2007).
2. Derynck, R. & Miyazono, K. (eds) The TGF-β Family (Cold Spring Harbor Press, 2008).
3. Derynck, R. & Akhurst, R. J. Differentiation plasticity regulated by TGF-β family proteins in development and disease. Nature Cell Biol. 9, 1000-1004 (2007).
4. Flavell, R. A., Sanjabi, S., Wrzesinski, S. H. & Licona-Limon, P. The polarization of immune cells in the tumour environment by TGFβ. Nature Rev. Immunol. 10, 554-567 (2010).
5. Mao, J. H. et al. Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility. Proc. Natl Acad. Sci. USA 103, 8125-8130 (2006).
6. Guo, X. & Wang, X. F. Signaling cross-talk between TGF-β/BMP and other pathways. Cell Res. 19, 71-88 (2009).
7. Conidi, A. et al. Few Smad proteins and many Smad-interacting proteins yield multiple functions and action modes in TGFβ/BMP signaling in vivo. Cytokine Growth Factor Rev. 22, 287-300 (2011).
8. Akhurst, R. J. TGFβ signaling in health and disease. Nature Genet. 36, 790-792 (2004).
9. Freimuth, J. et al. Epistatic interactions between Tgfb1 and genetic loci, Tgfbm2 and Tgfbm3, determine susceptibility to an asthmatic stimulus. Proc. Natl Acad. Sci. USA (in the press).
10. Anscher, M. S. et al. Small molecular inhibitor of transforming growth factor-β protects against development of radiation-induced lung injury. Int. J. Radiat. Oncol. Biol. Phys. 71, 829-837 (2008).
11. Neptune, E. R. et al. Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nature Genet. 33, 407-411 (2003).
12. Habashi, J. P. et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312, 117-121 (2006).
13. Roberts, A. B. & Wakefield, L. M. The two faces of transforming growth factor β in carcinogenesis. Proc. Natl Acad. Sci. USA 100, 8621-8623 (2003).
14. Massague, J. TGFβ in cancer. Cell 134, 215-230 (2008).
15. Levy, L. & Hill, C. S. Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 17, 41-58 (2006).
16. Hawinkels, L. J. & Ten Dijke, P. Exploring anti-TGF-β therapies in cancer and fibrosis. Growth Factors 29, 140-152 (2011).
17. Harradine, K. A. & Akhurst, R. J. Mutations of TGFβ signaling molecules in human disease. Ann. Med. 38, 403-414 (2006).
18. Millan, F. A., Denhez, F., Kondaiah, P. & Akhurst, R. J. Embryonic gene expression patterns of TGF β1, β2 and β3 suggest different developmental functions in vivo. Development 111, 131-143 (1991).
19. Kulkarni, A. B. et al. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl Acad. Sci. USA 90, 770-774 (1993).
20. Shull, M. M. et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359, 693-699 (1992).
21. Dickson, M. C. et al. Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice. Development 121, 1845-1854 (1995).
22. Sanford, L. P. et al. TG F β2 knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes. Development 124, 2659-2670 (1997).
23. Proetzel, G. et al. Transforming growth factor-β3 is required for secondary palate fusion. Nature Genet. 11, 409-414 (1995).
24. Schultz-Cherry, S., Ribeiro, S., Gentry, L. & Murphy-Ullrich, J. E. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-β in a chemically defined system. J. Biol. Chem. 269, 26775-26782 (1994).
25. Munger, J. S. et al. The integrin αvβ6 binds and activates latent TGF β1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96, 319-328 (1999).
26. Shi, M. et al. Latent TGF-β structure and activation. Nature 474, 343-349 (2011).
27. Shi, Y. & Massague, J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 11 3, 685-700 (2003).
28. Davis-Dusenbery, B. N. & Hata, A. Smad-mediated miRNA processing: a critical role for a conserved RNA sequence. RNA Biol. 8, 71-76 (2011).
29. Oft, M. et al. TGF-β1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 10, 2462-2477 (1996).
30. Massague, J. & Gomis, R. R. The logic of TGFβ signaling. FEBS Lett. 580, 2811-2820 (2006).
31. Massague, J. How cells read TGF-β signals. Nature Rev. Mol. Cell Biol. 1, 169-178 (2000).
32. Mehra, A. & Wrana, J. L. TGF-β and the Smad signal transduction pathway. Biochem. Cell Biol. 80, 605-622 (2002).
33. Padua, D. & Massague, J. Roles of TGFβ in metastasis. Cell Res. 19, 89-102 (2009).
34. Heldin, C. H., Landstrom, M. & Moustakas, A. Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr. Opin. Cell Biol. 21, 166-176 (2009).
35. Dooley, S. & ten Dijke, P. TGF-β in progression of liver disease. Cell Tissue Res. 347, 245-256 (2012).
36. Pardali, E. & Te n Dijke, P. TGFβ signaling and cardiovascular diseases. Int. J. Biol. Sci. 8, 195-213 (2012).
37. Derynck, R., Akhurst, R. J. & Balmain, A. TGF-β signaling in tumor suppression and cancer progression. Nature Genet. 29, 117-129 (2001).
38. Coffey, R. J. Jr. et al. Growth modulation of mouse keratinocytes by transforming growth factors. Cancer Res. 48, 1596-1602 (1988).
39. Gomis, R. R. et al. A FoxO-Smad synexpression group in human keratinocytes. Proc. Natl Acad. Sci. USA 103, 12747-12752 (2006).
40. Siegel, P. M., Shu, W. & Massague, J. Mad upregulation and Id2 repression accompany transforming growth factor (TGF)-β-mediated epithelial cell growth suppression. J. Biol. Chem. 278, 35444-35450 (2003).
41. Akhurst, R. J. The paradoxical TGF-β vasculopathies. Nature Genet. 44, 838-839 (2012).
42. Heldin, C. H., Rubin, K., Pietras, K. & Ostman, A. High interstitial fluid pressure-an obstacle in cancer therapy. Nature Rev. Cancer 4, 806-813 (2004).
43. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008).
44. Salnikov, A. V. et al. Inhibition of TGF-β modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab. Invest. 85, 512-521 (2005).
45. Willis, B. C. et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol. 166, 1321-1332 (2005).
46. Kim, K. K. et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl Acad. Sci. USA 103, 13180-13185 (2006).
47. Goumans, M. J., van Zonneveld, A. J. & ten Dijke, P. Transforming growth factor β-induced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis? Trends Cardiovasc. Med. 18, 293-298 (2008).
48. Sato, M., Muragaki, Y., Saika, S., Roberts, A. B. & Ooshima, A. Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J. Clin. Invest. 11 2, 1486-1494 (2003).
49. Lan, H. Y. Diverse roles of TGF-β/Smads in renal fibrosis and inflammation. Int. J. Biol. Sci. 7, 1056-1067 (2011).
50. Yao, E. H. et al. A pyrrole-imidazole polyamide targeting transforming growth factor-β1 inhibits restenosis and preserves endothelialization in the injured artery. Cardiovasc. Res. 81, 797-804 (2009).
51. Tsai, S. et al. TGF-β through Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation. Am. J. Physiol. Heart Circ. Physiol. 297, H540-H549 (2009).
52. Fu, K. et al. SM16, an orally active TGFß type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler. Thromb. Vasc. Biol. 28, 665-671 (2008).
53. Nishimura, G. et al. 5EF1 mediates TGF-ß signaling in vascular smooth muscle cell differentiation. Dev Cell 11, 93-104 (2006).
54. Diebold, R. J. et al. Early-onset multifocal inflammation in the transforming growth factor ß 1-null mouse is lymphocyte mediated. Proc. Natl Acad. Sci. USA 92, 12215-12219 (1995).
55. Rubtsov, Y. P. & Rudensky, A. Y. TGFß signalling in control of T-cell-mediated self-reactivity. Nature Rev. Immunol. 7, 443-453 (2007).
56. Ramesh, S., Wildey, G. M. & Howe, P. H. Transforming growth factor ß (TGFß)-induced apoptosis: the rise and fall of Bim. Cell Cycle 8, 11-17 (2009).
57. H17 cells by the DNA-binding inhibitor Id3. Nature Immunol. 12, 86-95 (2011).
58. Gorelik, L. & Flavell, R. A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-ß signaling in T cells. Nature Med. 7, 1118-1122 (2001).
59. Yamaguchi, Y, Tsumura, H., Miwa, M. & Inaba, K. Contrasting effects of TGF-ß 1 and TNF-a on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 15, 144-153 (1997).
60. Sato, K. et al. TGF-ß 1 reciprocally controls chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokine receptors. J. Immunol. 164, 2285-2295 (2000).
61. H17 and regulatory T cells. Nature 441, 235-238 (2006).
62. H17 lineage. Nature 441, 231-234 (2006).
63. H17 cell differentiation. Immunity 34, 396-408 (2011).
64. Annunziato, F & Romagnani, S. Mouse T helper 17 phenotype: not so different than in man after all. Cytokine 56, 112-115 (2011).
65. H17 cell differentiation. J. Exp. Med. 206, 2407-2416 (2009).
66. H17 cells in the absence of TGF-ß signalling. Nature 467, 967-971 (2010).
67. Laouar, Y., Sutterwala, F S., Gorelik, L. & Flavell, R. A. Transforming growth factor-ß controls T helper type 1 cell development through regulation of natural killer cell interferon-y. Nature Immunol. 6, 600-607 (2005).
68. Mantovani, A., Sozzani, S., Locati, M., Allavena, P. & Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549-555 (2002).
69. Fridlender, Z. G. et al. Polarization of tumor-associated neutrophil phenotype by TGF-ß: "N1" versus "N2" TAN. Cancer Cell 16, 183-194 (2009).
70. Schlingensiepen, R. et al. Intracerebral and intrathecal infusion of the TGF-ß2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety Oligonucleotides 15, 94-104 (2005).
71. Schlingensiepen, K. H. et al. Targeted tumor therapy with the TGF-ß2 antisense compound AP 12009. Cytokine Growth Factor Rev. 17, 129-139 (2006).
72. Jachimczak, P. et al. The effect of transforming growth factor-ß2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J. Neurosurg. 78, 944-951 (1993).
73. Schlingensiepen, K. H. et al. Transforming growth factor-ß2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci. 102, 1193-1200 (2011).
74. Bogdahn, U. et al. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 13, 132-142 (2011).
75. Santiago, B. et al. Topical application of a peptide inhibitor of transforming growth factor-β1 ameliorates bleomycin-induced skin fibrosis. J. Invest. Dermatol. 125, 450-455 (2005).
76. Llopiz, D. et al. Peptide inhibitors of transforming growth factor-β enhance the efficacy of antitumor immunotherapy. Int. J. Cancer 125, 2614-2623 (2009).
77. Hermida, N. et al. A synthetic peptide from transforming growth factor-β1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovascular Res. 81, 601-609 (2009).
78. Ezquerro, I. J. et al. A synthetic peptide from transforming growth factor β type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine 22, 12-20 (2003).
79. Nam, J. S. et al. An anti-transforming growth factor β antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res. 68, 3835-3843 (2008).
80. Ganapathy, V. et al. Targeting the transforming growth factor-β pathway inhibits human basal-like breast cancer metastasis. Mol. Cancer 9, 122 (2010).
81. Bouquet, F. et al. TG F β1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin. Cancer Res. 17, 6754-6765 (2011).
82. Rodon Ahnert, J. et al. First human dose (FHD) study of the oral transforming growth factor-β receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma. J. Clin. Oncol. 29, Abstract 3011 (2011).
83. Schlingensiepen, K. H., Fischer-Blass, B., Schmaus, S. & Ludwig, S. Antisense therapeutics for tumor treatment: the TGF-β2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res. 177, 137-150 (2008).
84. Oettle, H. et al. Final results of a phase I/II study in patients with pancreatic cancer, malignant melanoma, and colorectal carcinoma with trabedersen. J. Clin. Oncol. 30, Abstract 4034 (2012).
85. Nemunaitis, J. et al. Phase II study of belagenpumatucel-L, a transforming growth factor β-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 24, 4721-4730 (2006).
86. Nemunaitis, J. et al. Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther. 16, 620-624 (2009).
87. Bazhenova, L., Carrier, E., Shawler, D. & Fakhrai, H. Long-term survival in a phase II study of belagenpumatucel-L (antisense TGFβ vaccine) in non small-cell lung cancer (NSCLC). Cancer Res. 72, Abstract 5367 (2012).
88. Mead, A. L., Wong, T. T., Cordeiro, M. F., Anderson, I. K. & Khaw, P. T. Evaluation of anti-TGF-β2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest. Ophthalmol. Vis. Sci. 44, 3394-3401 (2003).
89. CAT-152 0201 Trabeculectomy Study Group. CAT-152 trabeculectomy study. Ophthalmology 11 4, 1950 (2007).
90. Denton, C. P. et al. Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 56, 323-333 (2007).
91. Lonning, S., Mannick, J. & McPherson, J. M. Antibody targeting of TGF-β in cancer patients. Curr. Pharm. Biotechnol. 12, 2176-2189 (2011).
92. Trachtman, H. et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 79, 1236-1243 (2011).
93. Morris, J. C. et al. Phase I/II study of GC1008: a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J. Clin. Oncol. 26, Abstract 9028 (2008).
94. Zhong, Z. et al. Anti-transforming growth factor β receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin. Cancer Res. 16, 1191-1205 (2010).
95. Van Aarsen, L. A. et al. Antibody-mediated blockade of integrin αvβ6 inhibits tumor progression in vivo by a transforming growth factor-β-regulated mechanism. Cancer Res. 68, 561-570 (2008).
96. Muraoka, R. S. et al. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109, 1551-1559 (2002).
97. Lu, A., Miao, M., Schoeb, T. R., Agarwal, A. & Murphy-Ullrich, J. E. Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am. J. Pathol. 178, 2573-2586 (2011).
98. Yingling, J. M., Blanchard, K. L. & Sawyer, J. S. Development of TGF-β signalling inhibitors for cancer therapy. Nature Rev. Drug Discov. 3, 1011-1022 (2004).
99. Bonafoux, D. & Lee, W. C. Strategies for TGF-β modulation: a review of recent patents. Expert Opin. Ther. Pat. 19, 1759-1769 (2009).
100. Saunier, E. F. & Akhurst, R. J. TGFβ inhibition for cancer therapy. Curr. Cancer Drug Targets 6, 519-532 (2006).
101. Akhurst, R. J. Large-and small-molecule inhibitors of transforming growth factor-beta signaling. Curr. Opin. Investig. Drugs 7, 513-521 (2006).
102. Washio, H. et al. Transcriptional inhibition of hypertrophic scars by a gene silencer, pyrrole-imidazole polyamide, targeting the TGF-β1 promoter. J. Invest. Dermatol. 131, 1987-1995 (2011).
103. Chen, M. et al. Pretranscriptional regulation of Tgf-β1 by PI polyamide prevents scarring and accelerates wound healing of the cornea after exposure to alkali. Mol. Ther. 18, 519-527 (2010).
104. Chen, H. Y. et al. The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes 60, 590-601 (2011).
105. Kapoor, S. Smad7 gene transfer therapy: therapeutic applications beyond colonic fibrosis. Eur. J. Clin. Invest. 38, 876-877; author reply 878-880 (2008).
106. Sheridan, C. Gene therapy finds its niche. Nature Biotech. 29, 121-128 (2011).
107. Foster, A. E. et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-β receptor. J. Immunother. 31, 500-505 (2008).
108. Rainusso, N. et al. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther. 19, 212-217 (2012).
109. Nakazawa, Y. et al. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol. Ther. 19, 2133-2143 (2011).
110. Ahmed, N. et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin. Cancer Res. 16, 474-485 (2010).
111. Ahmed, N. et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 67, 5957-5964 (2007).
112. Laverty, H. G. et al. Effects of avotermin (transforming growth factor β3) in a clinically relevant pig model of long, full-thickness incisional wounds. J. Cutan. Med. Surg. 14, 223-232 (2010).
113. Cohn, R. D. et al. Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. Nature Med. 13, 204-210 (2007).
114. Podowski, M. et al. Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. J. Clin. Invest. 122, 229-240 (2012).
115. Lanz, T. V. et al. Angiotensin II sustains brain inflammation in mice via TGF-ß. J. Clin. Invest. 120, 2782-2794 (2010).
116. Zhou, H., Latham, C. W., Zander, D. S., Margolin, S. B. & Visner, G. A. Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts. J. Heart Lung Transplant. 24, 1577-1585 (2005).
117. Taniguchi, H. et al. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir. Res. 12, 93 (2011).
118. Noble, P. W. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377, 1760-1769 (2011).
119. Grainger, D. J. et al. The serum concentration of active transforming growth factor-ß is severely depressed in advanced atherosclerosis. Nature Med. 1, 74-79 (1995).
120. Cui, W. et al. TGFß1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86, 531-542 (1996).
121. Bierie, B. & Moses, H. L. Gain or loss of TGFß signaling in mammary carcinoma cells can promote metastasis. Cell Cycle 8, 3319-3327 (2009).
122. Bierie, B. et al. Abrogation of TGF-ß signaling enhances chemokine production and correlates with prognosis in human breast cancer. J. Clin. Invest. 119, 1571-1582 (2009).
123. Larsson, J. et al. Abnormal angiogenesis but intact hematopoietic potential in TGF-ß type I receptor-deficient mice. EMBO J. 20, 1663-1673 (2001).
124. Akhurst, R. J. TGF-ß antagonists: why suppress a tumor suppressor? J. Clin. Invest. 109, 1533-1536 (2002).
125. Yang, Y. A. et al. Lifetime exposure to a soluble TGF-ß antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109, 1607-1615 (2002).
126. Anderton, M. J. et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol. Pathol. 39, 916-924 (2011).
127. Frazier, K. et al. Inhibition of ALK5 signaling induces physeal dysplasia in rats. Toxicol. Pathol. 35, 284-295 (2007).
128. Goudie, D. R. et al. Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1. Nature Genet. 43, 365-369 (2011).
129. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
130. Arnault, J. P. et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J. Clin. Oncol. 27, e59-e61 (2009).
131. Esser, A. C, Abril, A., Fayne, S. & Doyle, J. A. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J. Am. Acad. Dermatol. 50, S75-S77 (2004).
132. Su, F et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215 (2012).
133. Arnault, J. P. et al. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin. Cancer Res. 18, 263-272 (2012).
134. Singh, A. & Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751 (2010).
135. Shipitsin, M. et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 11, 259-273 (2007).
136. Ikushima, H. et al. Autocrine TGF-ß signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 5, 504-514 (2009).
137. high glioma-initiating cell population in human glioblastoma. Cancer Cell 18, 655-668 (2010).
138. Penuelas, S. et al. TGF-β increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 15, 315-327 (2009).
139. Naka, K. et al. TGF-β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 463, 676-680 (2010).
140. Bragado, P. et al. Microenvironmental signals dictate disseminated tumor cells (DTCs) fate through regulation of TGFβII and p38α. Cancer Res. 72 (Suppl. 1), Abstract 5234 (2012).
141. Biswas, T., Yang, J., Zhao, L. & Sun, L. Z. Development of murine models of breast cancer metastasis for the evaluation of the efficacy of TGF-β inhibitors as therapeutic agents. Cancer Res. 72 (Suppl. 1), Abstract 1366 (2012).
142. Ohmori, T., Yang, J. L., Price, J. O. & Arteaga, C. L. Blockade of tumor cell transforming growth factor-βs enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Exp. Cell Res. 245, 350-359 (1998).
143. Ehata, S. et al. Transforming growth factor-β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells. Oncogene 30, 1693-1705 (2011).
144. Tang, B. et al. Transforming growth factor-β can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res. 67, 8643-8652 (2007).
145. Quante, M. et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19, 257-272 (2011).
146. Hayashi, T. et al. Transforming growth factor β receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin. Cancer Res. 10, 7540-7546 (2004).
147. Bandyopadhyay, A. et al. Doxorubicin in combination with a small TGFβ inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS ONE 5, e10365 (2010).
148. Takeuchi, K. et al. TGF-β inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS ONE 5, e9870 (2010).
149. Yin, J. J. et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103, 197-206 (1999).
150. Shinto, O. et al. Combination effect of a TGF-β receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice. Cancer Sci. 101, 1846-1852 (2010).
151. Kano, M. R. et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc. Natl Acad. Sci. USA 104, 3460-3465 (2007).
152. Liu, Y. & Zeng, G. Cancer and innate immune system interactions: translational potentials for cancer immunotherapy. J. Immunother. 35, 299-308 (2012).
153. + T cells. Clin. Cancer Res. 16, 164-173 (2010).
154. + T cells activates the antitumor immune response cycle. Mol. Cancer Ther. 5, 1733-1743 (2006).
155. Wallace, A. et al. Transforming growth factor-β receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin. Cancer Res. 14, 3966-3974 (2008).
156. Connolly, E. C. et al. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long term TßRI/II kinase inhibition with LY2109761. Cancer Res. 71, 1-11 (2011).
157. Zhang, M. et al. Blockade of TGF-β signaling by the TGFßR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res. 71, 7155-7167 (2011).
158. Barcellos-Hoff, M. H. & Akhurst, R. J. Transforming growth factor-β in breast cancer: too much, too late. Breast Cancer Res. 11, 202 (2009).
159. Kirshner, J. et al. Inhibition of transforming growth factor-β1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Res. 66, 10861-10869 (2006).
160. Zhou, L. et al. Reduced SMAD7 leads to overactivation of TGF-β signaling in MDS that can be reversed by a specific inhibitor of TGF-β receptor I kinase. Cancer Res. 71, 955-963 (2011).
161. Cerri, S., Spagnolo, P., Luppi, F. & Richeldi, L. Management of idiopathic pulmonary fibrosis. Clin. Chest Med. 33, 85-94 (2012).
162. Sheppard, D. Transforming growth factor β: a central modulator of pulmonary and airway inflammation and fibrosis. Proc. Am. Thorac. Soc. 3, 413-417 (2006).
163. Katsumoto, T. R., Violette, S. M. & Sheppard, D. Blocking TGFβ via inhibition of the αvβ6 integrin: a possible therapy for systemic sclerosis interstitial lung disease. Int. J. Rheumatol. 2011, 208219 (2011).
164. Chapman, H. A. Epithelial-mesenchymal interactions in pulmonary fibrosis. Annu. Rev. Physiol. 73, 413-435 (2011).
165. Azuma, A. Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther. Adv. Respir. Dis. 6, 107-114 (2012).
166. Yamada, M. et al. Gene transfer of soluble transforming growth factor type II receptor by in vivo electroporation attenuates lung injury and fibrosis. J. Clin. Pathol. 60, 916-920 (2007).
167. Arribillaga, L. et al. Therapeutic effect of a peptide inhibitor of TGF-β on pulmonary fibrosis. Cytokine 53, 327-333 (2011).
168. Crunkhorn, S. Deal watch: Biogen acquires Stromedix to pursue novel fibrosis therapy. Nature Rev. Drug Discov. 11, 260 (2012).
169. Allison, M. Stromedix acquisition signals growing interest in fibrosis. Nature Biotech. 30, 375-376 (2012).
170. Liu, Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 69, 213-217 (2006).
171. Fragiadaki, M. & Mason, R. M. Epithelial-mesenchymal transition in renal fibrosis-evidence for and against. Int. J. Exp. Pathol. 92, 143-150 (2011).
172. Alan, C., Kocoglu, H., Altintas, R., Alici, B. & Resit Ersay, A. Protective effect of decorin on acute ischaemia-reperfusion injury in the rat kidney. Arch. Med. Sci. 7, 211-216 (2011).
173. Terada, Y. et al. Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney. Kidney Int. 61, S94-S98 (2002).
174. Lim, D. S. et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103, 789-791 (2001).
175. van Rooij, E. & Olson, E. N. Searching for miR-acles in cardiac fibrosis. Circ. Res. 104, 138-140 (2009).
176. Merkel, P. A. et al. Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis Rheum. 59, 699-705 (2008).
177. McCaffrey, T. A. TGF-β signaling in atherosclerosis and restenosis. Front. Biosci. (Schol. Ed.) 1, 236-245 (2009).
178. Friedl, R. et al. Intimal hyperplasia and expression of transforming growth factor-β1 in saphenous veins and internal mammary arteries before coronary artery surgery. Ann. Thorac. Surg. 78, 1312-1318 (2004).
179. Ranjzad, P., Salem, H. K. & Kingston, P. A. Adenovirus-mediated gene transfer of fibromodulin inhibits neointimal hyperplasia in an organ culture model of human saphenous vein graft disease. Gene Ther. 16, 1154-1162 (2009).
180. Kapur, N. K. et al. Inhibition of transforming growth factor-β restores endothelial thromboresistance in vein grafts. J. Vasc. Surg. 54, 1117-1123.e1 (2011).
181. Ramirez, F. & Dietz, H. C. Marfan syndrome: from molecular pathogenesis to clinical treatment. Curr. Opin. Genet. Dev. 17, 252-258 (2007).
182. Holm, T. M. et al. Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 332, 358-361 (2011).
183. 2 monoclonal antibody-a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology 109, 427-431 (2002).
184. 2 monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology 114, 1822-1830 (2007).
185. Fukuda, K., Chikama, T., Takahashi, M. & Nishida, T. Long-term follow-up after lamellar keratoplasty in a patient with bilateral idiopathic corneal keloid. Cornea 30, 1491-1494 (2011).
186. Benzinou, M. et al. Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nature Commun. 3, 616 (2012).
187. Bonyadi, M. et al. Mapping of a major genetic modifier of embryonic lethality in TGFβ1 knockout mice. Nature Genet. 15, 207-211 (1997).
188. Farrington, D. L. et al. Development and validation of a phosphorylated SMAD ex vivo stimulation assay. Biomarkers 12, 313-330 (2007).
189. + T reg cells. J. Exp. Med. 203, 1701-1711 (2006).
190. McClymont, S. A. et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J. Immunol. 186, 3918-3926 (2011).
191. You, S. et al. Adaptive TGF-β-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc. Natl Acad. Sci. USA 104, 6335-6340 (2007).
192. Clay, T. M., Hobeika, A. C., Mosca, P. J., Lyerly, H. K. & Morse, M. A. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin. Cancer Res. 7, 1127-1135 (2001).
193. Baselga, J. et al. TGF-β signalling-related markers in cancer patients with bone metastasis. Biomarkers 13, 217-236 (2008).
194. Bornstein, S. et al. Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J. Clin. Invest. 11 9, 3408-3419 (2009).
195. Lu, S. L. et al. Loss of transforming growth factor-β type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev. 20, 1331-1342 (2006).
196. Gomis, R. R., Alarcon, C., Nadal, C., Van Poznak, C. & Massague, J. C/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 10, 203-214 (2006).
197. Micalizzi, D. S. et al. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-β signaling. J. Clin. Invest. 11 9, 2678-2690 (2009).
198. Hannigan, A. et al. Epigenetic downregulation of human disabled homolog 2 switches TGF-β from a tumor suppressor to a tumor promoter. J. Clin. Invest. 120, 2842-2857 (2010).
199. Law, B. K. et al. Rapamycin potentiates transforming growth factor β-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol. Cell. Biol. 22, 8184-8198 (2002).
200. Engelman, J. A. & Settleman, J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 18, 73-79 (2008).
201. Corcoran, R. B. et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal. 3, ra84 (2010).
202. H17 cell differentiation and development of experimental autoimmune encephalomyelitis in mice. J. Clin. Invest. 120, 4445-4452 (2010).
203. H17 cell development and experimental autoimmune encephalomyelitis in mice. J. Clin. Invest. 120, 4436-4444 (2010).
204. Yadav, H. et al. Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling. Cell Metab. 14, 67-79 (2011).
205. Massague, J., Seoane, J. & Wotton, D. Smad transcription factors. Genes Dev. 19, 2783-2810 (2005).
206. Keller, B. et al. Interaction of TGFβ and BMP signaling pathways during chondrogenesis. PLoS ONE 6, e16421 (2011).
207. Montero, J. A., Lorda-Diez, C. I., Ganan, Y., Macias, D. & Hurle, J. M. Activin/TGFβ and BMP crosstalk determines digit chondrogenesis. Dev. Biol. 321, 343-356 (2008).
208. Goumans, M. J. et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFβ/ALK5 signaling. Mol. Cell 12, 817-828 (2003).
209. Hau, P. et al. Inhibition of TGF-β2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 17, 201-212 (2007).
210. Chamberlain, M. C. Convection-enhanced delivery of a transforming growth factor-β2 inhibitor trabedersen for recurrent high-grade gliomas: efficacy real or imagined?, in reference to Bogdahn et al. (Neuro-Oncology 2011;13: 132-142). Neuro Oncol. 13, 558-559; author reply 561-552 (2011).
211. Wick, W. & Weller, M. Trabedersen to target transforming growth factor-β: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13: 132-142). Neuro Oncol. 13, 559-560; author reply 561-552 (2011).
212. Roldan Urgoiti, G. B., Singh, A. D. & Easaw, J. C. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. J. Neurooncol. 108, 173-177 (2012).
213. Azaro, A. et al. The oral transforming growth factor-β (TGF-β) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: the first human dose study. J. Clin. Oncol. 30, Abstract 2042 (2012).
214. Occleston, N. L. et al. Discovery and development of avotermin (recombinant human transforming growth factor β3): a new class of prophylactic therapeutic for the improvement of scarring. Wound Repair Regen. 19 (Suppl. 1), S38-S48 (2011).
215. Platten, M. et al. N-[3, 4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-β relesase and reduces migration and invasiveness of human malignant glioma cells. Int. J. Cancer 93, 53-61 (2001).
216. Isaji, M. et al. Inhibitory effects of tranilast on the proliferation and functions of human pterygium-derived fibroblasts. Cornea 19, 364-368 (2000).
217. Schlingensiepen, K. H. et al. The TGF-β1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: preclinical studies. J. Clin. Oncol. 22, Abstract 3132 (2004).
218. Nam, J. S. et al. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor β in a mouse model of breast cancer. Cancer Res. 66, 6327-6335 (2006).
219. Melisi, D. et al. LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol. Cancer Ther. 7, 829-840 (2008).
220. Fransvea, E., Angelotti, U., Antonaci, S. & Giannelli, G. Blocking transforming growth factor-β up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 47, 1557-1566 (2008).
221. Mazzocca, A., Fransvea, E., Lavezzari, G., Antonaci, S. & Giannelli, G. Inhibition of transforming growth factor β receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 50, 1140-1151 (2009).
222. Zhang, B., Halder, S. K., Zhang, S. & Datta, P. K. Targeting transforming growth factor-β signaling in liver metastasis of colon cancer. Cancer Lett. 277, 114-120 (2009).
223. Inman, G. J. et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62, 65-74 (2002).
224. Hjelmeland, M. D. et al. SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol. Cancer Ther. 3, 737-745 (2004).
225. DaCosta Byfield, S., Major, C., Laping, N. J. & Roberts, A. B. SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 65, 744-752 (2004).
226. Uhl, M. et al. SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64, 7954-7961 (2004).
227. Ge, R. et al. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-β type I receptor kinase in vivo. Clin. Cancer Res. 12, 4315-4330 (2006).
228. Suzuki, E. et al. A novel small-molecule inhibitor of transforming growth factor β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res. 67, 2351-2359 (2007).
229. Kim, S. et al. Systemic blockade of transforming growth factor-β signaling augments the efficacy of immunogene therapy. Cancer Res. 68, 10247-10256 (2008).
230. Gellibert, F. et al. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl] pyridin-2-yl}-N-(tetrahydro-2H-pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-β type I receptor inhibitor. J. Med. Chem. 49, 2210-2221 (2006).
231. Petersen, M. et al. Oral administration of GW788388, an inhibitor of TGF-β type I and II receptor kinases, decreases renal fibrosis. Kidney Int. 73, 705-715 (2008).
232. Tan, S. M., Zhang, Y., Connelly, K. A., Gilbert, R. E. & Kelly, D. J. Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 298, H1415-H1425 (2010).